Biopharmaceutical CMO and CRO Market Size to Reach US$ 59.4 Bn by 2030

New York, Oct. 05, 2021 (GLOBE NEWSWIRE) -- New York, Oct 05, 2021 (GLOBE NEWSWIRE) – According to Precedence Research, the global biopharmaceutical CMO and CRO market was valued at US$ 29.1 billion in 2020. The biopharmaceutical CMO and CRO is an integral part of the biopharmaceutical industry. The CMO and CRO are directly linked and influenced by the biopharmaceutical industry. CMO stands for contract manufacturing organizations that sets up manufacturing plants and produces biopharmaceutical products on large scale on contract basis. These organizations are manufacturing specialists that saves cost and time of the contractor and provides efficient output. The CRO refers to the contract research organizations that undertake the task of various research and developmental activities assigned by the contractors and helps in the development of new and innovative drugs. The rising demand for the biopharmaceutical drugs among the consumers has contributed to the rapid growth of the biopharmaceutical industry. Biopharmaceutical is rapidly growing globally and it alone accounts for over 20% of the total pharmaceutical industry. Growing investments and manufacturing contracts by the small and medium sized pharma industry players is propelling the growth of the CMO and CRO in the market significantly.

Get the Sample Pages of Report for More Understanding@ https://www.precedenceresearch.com/sample/1289

Crucial factors accountable for market growth are:

• Rapidly growing biopharmaceutical industry
• Rising demand for the biopharmaceutical products
• Increased participation of medium and small-sized enterprises in biologics
• Growing government expenditure on building sophisticated healthcare infrastructure
• Increasing adoption of biopharma drugs and therapeutics
• Rising burden of diseases amongst the population
• Presence of numerous CMOs and CROs in the market
  
  

Scope of the Biopharmaceutical CMO and CRO Market Report

Regional Snapshots

North America is the leading biopharmaceutical CMO and CRO market. The US accounts for around 33.33% of the global biopharmaceutical CMO market and is also the leader in biopharmaceutical CRO market. As per the Pharmaceutical Research and Manufacturers Association, US has the property rights on majority of the new medicines. North America is characterized by supportive setting for the commercialization and development of medicines, rewards to the developers in the form of intellectual property rights, and supportive regulatory framework for the biopharmaceuticals. This helps in attracting capital investments in North America region for the development of biopharmaceutical companies. This is a significant growth factor that boosts the growth and development of the biopharmaceutical CMO and CRO market in the region.

Get Customization on this Research Report@ https://www.precedenceresearch.com/customization/1289

Click here to view full report Table of Content

Asia Pacific is estimated to be the fastest-growing region, owing to enhanced regulatory framework regarding the biopharmaceuticals, greater supply of capital, and support from the government. In South Korea, the Samsung Biologics witnessed a spike in its sales by 56% in 2017. Further, the Celltrion Group of South Korea acquired European Medicines Agency approval for it biosimilar product called Herzuma, in 2018. Further, in India, Biocon received FDA approval for its biosimilar product called Ogivri in 2017. China, the second largest market for the biopharmaceuticals is attracting FDIs for setting up manufacturing units that exponentially propels the biopharmaceutical CMO and CRO market growth in Asia Pacific region.

Report Highlights

• By service, the contract manufacturing segment led the global biopharmaceutical CMO and CRO market with remarkable revenue share in 2020. This is attributed to the growing participation of the small and medium conventional pharmaceutical developers in the biopharmaceutical industry owing to its market attractiveness.
  
  
• By source, the mammalian segment led the global biopharmaceutical CMO and CRO market with remarkable revenue share in 2020. This is attributed to the growing importance of biotherapies namely, monoclonal antibodies, vaccines, and blood factors are developed using mammalian cell culture. Moreover, the antibody products are the dominant commercial products that foster the segment growth.
  
  
• By product type, the biologics segment led the global biopharmaceutical CMO and CRO market with remarkable revenue share in 2020. Biologics gained traction when it opened up the opportunities for the treatment of cancer. Moreover, higher approval rate of biologic medicines is fostering its adoption at a rapid pace among the consumers.
  
  

Related Reports

• Generic Drugs Market
• Home Healthcare Market
• Behavioral Health Market
• Smart Healthcare Market

Drivers

The global biopharmaceutical CMO and CRO market is primarily driven by the increasing popularity and increasing investments by the key players in the biopharmaceutical industry for the development of cost-effective and innovative drugs.

Restraints

The lack of proper healthcare infrastructure in the underdeveloped economies, lack of awareness regarding technologically advance biopharma products, and high costs involved are the major factors that may hamper the market growth.

Opportunities

The growing research and development activities carried on by the key market players to develop effective drugs and medicines for various serious illnesses and disease like cancer may open up new opportunities in the upcoming future.

Challenges

Lack of adequate capital in the hands of the small pharmaceutical developers who have interests in shifting towards the biopharmaceuticals is a major challenge that may slow down the growth of the global biopharmaceutical CMO and CRO market.

Recent Developments

• In May 2019, Samsung Biologics entered into a contract with GI Innovation for development of Immunochemotherapy. Under this contract, Samsung Biologics will develop a new drug through a combination of protein drugs and human micro-organisms.
  
  

The key players operating in the biopharmaceutical CMO and CRO market are Lonza, Samsung Biologics, Patheon, CMC Biologics, TOYOBO Co. Ltd., JRS Pharma, RentschlerBiotechnologie, FUJIFILM Diosynth Biotechnologies, WuXi Biologics, BoehringerIngelheim, PRA Health Sciences, LabCorp.

Segments Covered in the Report

By Service

• Contract Manufacturing
  • Process Development
    • Upstream
    • Downstream
  • Fill & Finish Operations
  • Packaging
  • Analytical & QC studies
• Contract Research
  • Inflammation & Immunology
  • Oncology
  • Neuroscience
  • Cardiology
  • Others
    
    

By Source

• Mammalian
• Non-Mammalian

By Product

• Biosimilars
• Biologics
  • Vaccines
  • Monoclonal antibodies (MABs)
  • Recombinant Proteins
  • Antisense, RNAi, & Molecular Therapy
  • Others
    
    

By Geography

• North America
• Europe
• Asia Pacific
• MEAN
• Rest of the World
  
  

Buy this Premium Research Report@ https://www.precedenceresearch.com/checkout/1289

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 9197 992 333

About Us

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

For Latest Update Follow Us:

https://www.linkedin.com/company/precedence-research/

https://www.facebook.com/precedenceresearch/

https://twitter.com/Precedence_R